Enhancement of solubility and dissolution rate of different forms of atorvastatin calcium direct compression tablet formulas

Farmacia

Volumn 57, Issue 3, 2009, Pages 290-300

  Ahjel, Salam W ^a   Lupuleasa, Dumitru ^b  

^a UNIVERSITY OF BAGHDAD   (Iraq)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Alkalinizing agent; Atorvastatin calcium; Buffering agent; Direct compression; Dissolution rate

Indexed keywords

ATORVASTATIN; CROSCARMELLOSE SODIUM; DISODIUM HYDROGEN PHOSPHATE; LACTOSE; MAGNESIUM HYDROXIDE; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE;

ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; PH; TABLET COMPRESSION; TABLET FORMULATION; TABLET MANUFACTURE;

EID: 69249202582     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Colhoun HM., Betteridge DJ., Durrington PN., et al - Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial; Lancet. 2004; 364:685
2. Pekkanen J., Linn S., Heiss G., et al. - Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease; N. Eng. J. Med.1990; 322:1700
3. Lennernas H., Fager G. - Pharmacodynamics and pharmacokinetics of the HMGCoA reductase inhibitors: similarities and differences; Clin. Pharmacokinetics. 1997; 32: 403-425
4. Shangraw R. F. (1989) - Compressed Tablets by Direct Compression Granulation Pharmaceutical Dosage Form; 2nd ed, Marcel Dekker, USA, 1989, vol. 1, 195-246
5. Jones P., Kafonek S., Laurora I., et al. - Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study); Am. J. Cardio. 1998; 81:582-587
6. Istvan ES., Deisenhofer J. - The structure of the catalytic portion of human HMGCoA reductase; Biochim. Biophys. Acta. 2000; 1529:9-18
7. Martin A.; Bustamante P. Chun A.H.C.- Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences, B.I.Waverly Pvt. Ltd.: New Delhi, 1994, 257
8. Klaus, Florey. Analytical Profiles of Drug Substances, Academic Press, Inc., New York, 2004, 577
9. United States Pharmacopeia, Rockville, Maryland: United States Pharmacopeial Convention, Inc. 2003, 2125-2126
10. Taylor M, Ginsburg J, Hickey A, Gheyas F. Composite method to quantify powder flow as a screening tablet or capsule formulation development. AAPS PharmSciTech. 2000; 1: E18
11. Bauer S, Mwinyi J, Stoeckle A, Gerloff T and Roots I. Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection, Journal of Chromatography B 2005; 818: 257-262
12. Bullen WW, Miller RA and Hayes RN. Development and validation of a highperformance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma, Journal of American Society for Mass Spectrometry 1999; 10: 55-66
13. Dumousseaux C, Muramatsu S, Takasaki W and Takahagi H. Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laserinduced fluorescence detection after immobilized antibody extraction, Journal of Pharmaceutical Sciences. 1994; 83: 1630-1636
14. Corina-Cristina Aramǎ, Ioana Drǎghici, Crina-Maria Monciu, Angela Nedelcu, Alexandra Neagu, Clementina Costantinescu, Assay of some hypocholesterolemiant substances (lovastatin, simvastatin) using NP-HPLC, Farmacia, 2007, LV (3), 267- 273
15. Ioana Drǎghici, Angela Nedelcu, Crina-Maria Monciu, Corina Aramǎ, Derivative spectrometry in the assay of simvastatin and lovastatin, Farmacia, 2008, LVI (1), 5-14